Skip to content

Study of brain PET/CT in autoimmune encephalitis

Prospective study of clinical value of brain PET/CT in pediatric autoimmune encephalitis

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036540
Enrollment
Unknown
Registered
2020-08-24
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune encephalitis

Interventions

Gold Standard:1. Neuron antibody is positive. 2. Immunotherapy is effecitve.

Sponsors

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 16 Years

Inclusion criteria

Inclusion criteria: (1) Clinical manifestations include developmental retardation, language disorder, abnormal mental behavior, epileptic seizure, cognitive impairment, autonomic nervous dysfunction, etc.; (2) One of the auxiliary examinations was positive: cerebrospinal fluid immune damage, serological immune abnormality, increased erythrocyte sedimentation rate, increased inflammatory factors, abnormal electroencephalogram, and MR abnormality; (3) Exclude other diseases.

Exclusion criteria

Exclusion criteria: (1) Patients with definite brain injury or other neurological diseases; (2) Has had the related immunotherapy or the treatment might influence brain function; (3) Fail to cooperate with the completion of PET/CT examination; (4) The claustrophobic; (5) Drug addicts.

Design outcomes

Primary

MeasureTime frame
SEN, SPE, ACC, AUC of ROC;

Countries

China

Contacts

Public ContactYafu Yin

Xinhua Hospital affiliated to Shanghai Jiao Tong Universtiy School of Medicine

yinyf-2001@163.com+86 13472594238

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026